KNSA Earnings Date 2026
Kiniksa Pharmaceuticals Ltd earnings schedule and quarterly results
Next Earnings Date
TBD
Current Stock Price
$79.40
+0.15% today
Earnings Metrics
EPS (TTM)
$0.45
P/E Ratio
91.4
Revenue Growth
61.2%
Market Cap
$3.7B
Earnings History
| Quarter | EPS | Revenue | Net Income |
|---|---|---|---|
| Q4 2024 | $-0.60 | $0.42B | $-0.04B |
| Q4 2023 | $0.20 | $0.27B | $0.01B |
Trading Around KNSA Earnings
Before Earnings
- Review analyst expectations and consensus estimates
- Check options implied volatility for expected move
- Consider historical earnings surprises
- Monitor pre-announcement guidance
After Earnings
- Compare actual results to estimates
- Listen to the earnings call for guidance
- Watch for analyst rating changes
- Monitor institutional buying/selling
Get Full KNSA Analysis
DCF valuation, AI insights, and institutional ownership data
Frequently Asked Questions
When is KNSA next earnings date?
KNSA (Kiniksa Pharmaceuticals Ltd) has not yet announced its next earnings date. Check back for updates on the upcoming earnings schedule.
What is KNSA earnings per share (EPS)?
KNSA's current earnings per share (EPS) is $0.45. With a P/E ratio of 91.4, the market values each dollar of earnings at $91.4.
How often does KNSA report earnings?
Like most publicly traded US companies, KNSA (Kiniksa Pharmaceuticals Ltd) reports earnings quarterly, typically within 4-6 weeks after each fiscal quarter ends. The company holds an earnings call to discuss results with analysts.
What time does KNSA report earnings?
KNSA typically reports earnings either before market open (BMO) or after market close (AMC). The exact time is usually announced a few days before the earnings date. Check the investor relations page for specific timing.
How has KNSA performed in recent earnings?
In the most recent quarter (Q4 2024), KNSA reported EPS of $-0.60 on revenue of $0.42B.
What do analysts expect for KNSA earnings?
Analyst expectations for KNSA earnings can vary. The company has shown positive revenue growth of 61.2%. View the full analyst ratings page for detailed expectations.